Functional Concept
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset
Vision, hydrocortisone, Bioscience
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera
Future-proofing gene therapy assays: Validation strategies for long-term success
Long-term, Validation, Biological Assay, Develop
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment